Melinta Therapeutics, Inc. Common Stock
MLNT
MLNT was delisted on the 10th of January, 2020.
87 hedge funds and large institutions have $246M invested in Melinta Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 39 increasing their positions, 13 reducing their positions, and 15 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 13
81% more capital invested
Capital invested by funds: $136M → $246M (+$110M)
27% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 15
5% more funds holding
Funds holding: 83 → 87 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less call options, than puts
Call options by funds: $695K | Put options by funds: $706K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OH
Oikos Holdings
New York
|
+$56.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$33.5M |
| 3 |
First Manhattan
New York
|
+$8.64M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.29M |
| 5 |
DM
Deerfield Management
New York
|
+$6.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$1.14M |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$381K |
| 3 |
FTIOP
Fiduciary Trust International of Pennsylvania
Radnor,
Pennsylvania
|
-$243K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$208K |
| 5 |
SDIC
South Dakota Investment Council
Sioux Falls,
South Dakota
|
-$179K |
MLNT Hedge Fund Activity: Q2 2018 in Review
87 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Melinta Therapeutics, Inc. Common Stock (MLNT) for Q2 2018, worth a combined $246M — up 81% from $136M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new MLNT positions and 15 closed out — a net gain of 4 holders — while 39 added to existing stakes and 13 trimmed.
The largest buyer was Oikos Holdings, adding an estimated $56.7M. The largest seller was Man Group, exiting entirely with an estimated $1.14M sold.
- 87 institutional investors held Melinta Therapeutics, Inc. Common Stock (MLNT) as of Q2 2018, up from 83 in Q1 2018.
- Funds reported $246M of Melinta Therapeutics, Inc. Common Stock stock for Q2 2018, up 81% quarter-over-quarter.
- 19 funds opened new Melinta Therapeutics, Inc. Common Stock positions in Q2 2018 and 15 closed out, a net change of +4 holders.
- The largest Melinta Therapeutics, Inc. Common Stock buyer in Q2 2018 was Oikos Holdings, an estimated $56.7M added.
- The largest Melinta Therapeutics, Inc. Common Stock seller in Q2 2018 was Man Group, an estimated $1.14M sold.
Based on aggregated 13F filings for Q2 2018.